Wastyk and Sonnenburg's 2021 Cell paper — the Stanford crossover trial that showed six servings per day of fermented foods reduced 19 inflammatory cytokines and increased microbiome diversity over ten weeks — has held up under three years of follow-up scrutiny. The replication picture is among the cleanest in the recent gut-immunology literature.

The 2026 follow-up cohort, run by the same group, tracked 142 of the original participants for an additional 24 months. The headline persistence finding: participants who maintained at least three daily servings of fermented foods retained roughly 71% of the cytokine reduction at month 36, versus near-complete reversion in the discontinuation arm. The microbiome diversity gains were similarly persistence-dependent.

The specific foods used in the trial — yogurt, kefir, kombucha, lacto-fermented vegetables, kimchi, and a small amount of fermented cottage cheese — were chosen for accessibility rather than mechanism, and the trial did not power any single-food analyses. The accumulated observational evidence from the persistence cohort suggests live-culture dairy and lacto-fermented vegetables carry the larger share of the immune signal, with kombucha contributing meaningfully less.

The mechanism remains incompletely understood. The Sonnenburg group's working model is that fermented foods deliver a combination of live microbes, microbial metabolites (short-chain fatty acids, bacteriocins), and modified food matrices that collectively shift mucosal immune tone. The trial did not establish causality for any single component.

The practical takeaway for clinicians is unusually robust by nutrition-trial standards: regular fermented food consumption is a low-cost, low-risk intervention with consistent immunological signal across multiple endpoints and a now-documented persistence requirement. The dose-response curve flattens above roughly four daily servings.